Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Carcinoma, Neuroendocrine 1

Interventions

Specimen Handling 613 pembrolizumab 568 Magnetic Resonance Spectroscopy 538 Carboplatin 429 Cyclophosphamide 381 Cisplatin 374 Biopsy 355 Paclitaxel 312 Nivolumab 307 Gemcitabine 302 Radiotherapy 260 Bevacizumab 237 Dexamethasone 213 fludarabine 207 Docetaxel 189 durvalumab 181 atezolizumab 175 Oxaliplatin 171 Rituximab 167 Fluorouracil 167 venetoclax 166 Pemetrexed 164 Doxorubicin 161 Capecitabine 158 Radiation 157 Radiosurgery 147 Etoposide 138 Leucovorin 134 Ipilimumab 134 Lenalidomide 132

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Interventional × DLL3 protein, human × 90 days × Clear all

NCT06893783 2026-04-13

DeLLight

Asan Medical Center

Phase 2 Recruiting

Carcinoma, Neuroendocrine

Data powered by HemOnc (CC BY 4.0) Colophon ⚡